Taysha Gene Therapies, Inc.
No enriched coverage for $TSHA in the last 7 days.
No SEC Form 4 filings for $TSHA in the last 30 days.
See all $TSHA insider activity →Red Cat (RCAT) analysts predict 115% upside to $18 per share despite rising expenses. Taysha (TSHA) advances TSHA-102 for Rett syndrome, awaiting FDA application. Solaris (SLSR) eyes 118% gain if Warintza copper project succeeds, pending feasibility study.
Taysha Gene Therapies (TSHA) reported Q2 2026 earnings, with a net loss of $46.6M, up from $26.9M in the prior year. R&D expenses rose to $38.6M, and cash reserves totaled $455.4M. The company completed dosing in REVEAL and ASPIRE trials for TSHA-102, a gene therapy for Rett syndrome, with 100% of Part A patients meeting responder status. Management expects regulatory discussions in H1 2027 and extended cash runway into H2 2028.
Taysha Gene Therapies (TSHA) shares fell 7% after the company reported a wider-than-expected Q2 loss. EPS was -$0.13 vs -$0.12 consensus, and net loss rose to $46.6M from $26.9M a year earlier, driven by higher R&D and G&A. Cash totaled $455.4M after a June 2026 follow-on financing.
Recent TSHA coverage spans financial news, earnings and corporate actions.
Clinical progress could spark significant move if data are positive.
Clinical and regulatory path progress plus a large cash raise increases near-term visibility for a BLA submission timeline.
The earnings miss and larger net loss shift near-term focus to cash burn and runway ahead of 2027 BLA-enabling milestones.
The filing adds concrete clinical and regulatory timing catalysts (6-month interim analysis basis for BLA, FDA feedback in 1H 2027) plus cash runway extension via a $230M follow-on.
The priced equity raise is a near-term dilution overhang, but the size and proceeds can also extend cash runway for TSHA-102 development.
AlphAI scores every news story that mentions TSHA with an AI model for sentiment and relevance, and aggregates insider trades from Taysha Gene Therapies, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Red Cat (RCAT) analysts predict 115% upside to $18 per share despite rising expenses. Taysha (TSHA) advances TSHA-102 for Rett syndrome, awaiting FDA application. Solaris (SLSR) eyes 118% gain if Warintza copper project succeeds, pending feasibility study.
2 min readTaysha Gene Therapies (TSHA) reported Q2 2026 earnings, with a net loss of $46.6M, up from $26.9M in the prior year. R&D expenses rose to $38.6M, and cash reserves totaled $455.4M. The company completed dosing in REVEAL and ASPIRE trials for TSHA-102, a gene therapy for Rett syndrome, with 100% of Part A patients meeting responder status. Management expects regulatory discussions in H1 2027 and extended cash runway into H2 2028.
6 min readTaysha Gene Therapies (TSHA) shares fell 7% after the company reported a wider-than-expected Q2 loss. EPS was -$0.13 vs -$0.12 consensus, and net loss rose to $46.6M from $26.9M a year earlier, driven by higher R&D and G&A. Cash totaled $455.4M after a June 2026 follow-on financing.
3 min readTaysha Gene Therapies, Inc. (TSHA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6-month interim analysis
6 min readTaysha Gene Therapies (NASDAQ:TSHA) priced an underwritten public offering of 32.5M shares at $6 each on June 24, plus prepaid warrants for 833,333 shares at $5.999 per warrant. The company expects about $200M gross proceeds and a 30-day option for up to 5M more shares. Bank of America raised its TSHA target to $10 from $9 and reiterated Buy after Part A REVEAL Rett syndrome study updates.
4 min readTaysha Gene Therapies said its R&D chief sold about $1.2 million of stock under a 10b5-1 plan, after a 149% share run. The executive still holds 936,410 shares. The company also reaffirmed FDA alignment for TSHA-102’s BLA pathway, citing REVEAL trial dosing completion of 17 patients and early durable results, with $276.6 million cash into 2028.
4 min readNagendran Sukumar (President and Head of R&D) sold 200,000 shares of Taysha Gene Therapies, Inc. (TSHA) at $6.24 ($1.25M total) on 2026-07-10 under a Rule 10b5-1 trading plan.
1 min readTaysha Gene Therapies, Inc. (TSHA) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d121397dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 Taysha Gene Therapies, Inc. Common Stock Pre-Funded Warrants Underwriting Agreement June 24, 2026 Jefferies LLC Goldman Sachs & Co. LLC As representatives of the several Underwriters named in Schedule I hereto c/o Jefferies LLC
4 min readTaysha Gene Therapies, Inc. (NASDAQ: TSHA) has announced the agenda for its annual stockholder meeting on June 1, 2026, which includes voting on the election of two Class III directors, the ratification of Deloitte & Touche LLP as the independent auditor, and a non-binding advisory vote on executive compensation. Stockholders will also decide the preferred frequency for future "say-on-pay" votes. The proxy statement details executive compensation for 2025, with CEO Sean Nolan receiving over $4 million, and lists major beneficial owners.
3 min readA Form 144 filing indicates that Sukumar Nagendran, an insider at Taysha Gene Therapies (NASDAQ: TSHA), proposes to sell 200,000 shares of the company's stock. The proposed sale, dated January 12, 2026, is valued at $942,740 and includes previously granted RSUs and stock options. This is a routine disclosure required for insider sales, providing transparency about the planned transaction.
2 min read
